Latest Utilities News

Vanadium Resources raises about A$1 million through a placement to fund studies and site agreements for its Steelpoortdrift Vanadium Project and next-gen V-Iron Plant, aiming to supply Western critical mineral markets.

X2M Connect is accelerating its transition to a high-margin SaaS model while trimming debt and growing its footprint across Asia-Pacific and the Middle East.

TrivarX has made significant strides in preparing its Stabl-Im stable isotope imaging platform for Phase 1 clinical trials, backed by strengthened leadership and a solid cash reserve of $2.91 million.

Pointerra Limited delivered a 214% jump in Q3 FY26 customer receipts to A$2.2 million, driven by milestone invoicing and new Tier 1 utility contracts, edging closer to operating cashflow breakeven.

Rhythm Biosciences marked a pivotal shift from development to commercial diagnostics in Q3 FY26, recording its first ColoSTAT® clinical sale and initiating NHS England evaluation while expanding geneType™ partnerships across Asia and Australia.

Artrya has fully integrated its Salix platform at Tanner Health, is preparing two more US sites for launch, and is finalising FDA submission for its Coronary Flow module, backed by a strong cash position of $76.6 million.

Orthocell has initiated commercial sales of its Remplir nerve repair device in Canada, leveraging a distributor-led model to penetrate a US$75 million market and setting the stage for broader North American expansion.

Epiminder has ramped up enrolment in its DETECT study, contracting 18 US medical centres and maintaining a robust $83.8 million cash position to fund its Minder device commercialisation through 2028.

Powerhouse Ventures holds $6.14 million in liquid assets and advances new technology fund launch despite challenging market conditions.

European Metals Holdings has secured critical regulatory milestones for its Cinovec Lithium Project, submitting the full Environmental Impact Assessment and obtaining Regional Rezoning approval. The company also raised A$3.46 million to support ongoing development.

Neurotech International has opened its first Phase 3 clinical site for NTI164 targeting Autism Spectrum Disorder, reported positive 90-day toxicology results, and launched a new Rett syndrome research collaboration.

Minerals 260 has secured a $59.1 million fixed-price contract with ATCO to build a 400-person accommodation village at its Bullabulling Gold Project, marking a key step towards construction readiness.